The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Pauwels, Bea ^a   Korst, Annelies E C ^a   Pattyn, Greet G O ^a   Lambrechts, Hilde A J ^a   Kamphuis, Juliette A E ^b   De Pooter, Christel M J ^c   Peters, Godefridus J ^b   Lardon, Filip ^a   Vermorken, Jan B ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SINT AUGUSTINUS HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCYTIDINE KINASE; GEMCITABINE; SULFORHODAMINE B;

ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; RADIOSENSITIZATION;

CELL SURVIVAL; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DNA REPAIR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 33746324243     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-142     Document Type: Article

References (62)

1. Storniolo AM, Allerheiligen SRB, Pearce H: Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997, 24(2 Suppl 7):S7-2-S7-7. Review
2. Peters GJ, Ruiz van Haperen VWT, Bergman AM, Veerman G, Smitskamp-Wilms E, Van Moorsel CJA, Kuiper CM, Braakhuis BJM: Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 1996, 23:16-24.
3. Rockwell S, Grindley GB: Effect of 2′-2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncology Research 1992, 4:151-155.
4. Milas L, Fujii T, Hunter N, Elshaikh M, Mason K, Plunkett W, Ang KK, Hittelman W: Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999, 59:107-114.
5. Mason KA, Milas L, Hunter NR, Elshaikh M, Buchmiller L, Kishi K, Hittelman KW, Ang KK: Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 1999, 44:1125-1135.
6. Chen M, Hough AM, Lawrence TS: The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol 2000, 45:369-374.
7. Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, Weber KJ: Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 1998, 41:875-882.
8. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach S: Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 1996, 34:867-872.
9. Lawrence TS, Davis MA, Hough A, Rehemtulla A: The role of apoptosis in 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res 2001, 7:314-319.
10. Mose S, Karapetian M, Juling Pohlit L, Taborski B, Damrau M, Ramm U, Rahn A, Bottcher HD: Radiation enhancement of gemcitabinein two human squamous cell carcinoma cell lines. AnticancerRes 2000, 20:401-405.
11. Ostruszka LJ, Shewach DS: The role of cell cycleprogression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine. Cancer Res 2000, 60:6080-6088.
12. Rosier JF, Beauduin M, Bruniaux M, De Bast M, De Coster B, Octave Prignot M, Scalliet P, Gregoire V: The effect of 2′-2′difluorode-oxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity. Int J Radiat Biol 1999, 75:245-251.
13. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS: Metabolism of 2′,2′'-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994, 54:3218-3223.
14. Sangar VK, Cowan R, Margison GP, Hendry JH, Clarke NW: An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines. Br J Cancer 2004, 90:542-548.
15. Genc M, Kreder NC, Barten van Rijbroek A, Stalpers LJA, Haveman J: Enhancement of effects of irradiation by gemcitabine in a glioblastoma cell line and cell line spheroids. J Cancer Res Clin Oncol 2004, 130:45-51.
16. Joschko MA, Webster LK, Groves J, Yuen K, Palatsides M, Ball DL, Millward MJ: Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiat Oncol Invest 1997, 5:62-71.
17. Eisbruch A, Shewach DS, Bradford CR, Littles JF, Teknos TN, Chepeha DB, Marentette LJ, Terrell JE, Hogikyan ND, Dawson LA, Urba S, Wolf GT, Lawrence TS: Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study. J Clin Oncol 2001, 19:792-799.
18. Cetina L, Rivera L, Candelaria M, de la Garza J, Duenas Gonzalez A: Chemoradiation with gemcitabine for cervical cancer in patients with renal failure. Anticancer Drugs 2004, 15:761-766.
19. Langer CJ: The emerging role of gemcitabine in combination with radiation in locally advanced, unresectable non-small-cell lung cancer. Clin Lung Cancer 2003, 4(suppl 2):S45-9.
20. Lin LL, Picus J, Drebin JA, Linehan DC, Solis J, Strasberg SM, Tan B, Thorstad WL, Myerson R: A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma. Am J ClinOncol 2005, 28:234-41.
21. Sangar VK, McBain CA, Lyons J, Ramani VA, Logue JP, Wylie JP, Clarke NW, Cowan RA: Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys 2005, 61:420-5.
22. Maraveyas A, Sgouros J, Upadhyay S, Abdel Hamid AH, Holmes M, Lind M: Gemcitabine twice weekly as a radiosensitiser for the treatmentof brain metastases in patients with carcinoma: a phase I study. Br J Cancer 2005, 92:815-9.
23. Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, Kagami Y, Ikeda H: Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 2004, 91:673-677.
24. Kent E, Sandler H, Montie J, Lee C, Herman J, Esper P, Fardig J, Smith DC: Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: Results of a phase I trial. J Clin Oncol 2004, 22:2540-2545.
25. Pipas JM, Mitchell SE, Barth RJ, Vera Gimon R, Rathmann J, Meyer LP, Wagman RS, Lewis LD, McDonnell C, Colacchio TA, Perez RP, Amer Brachytherapy Soc: Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2001, 50:1317-1322.
26. Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T: A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 2002, 86:1551-1554.
27. de Lange SM, van Groeningen CJ, Meijer OWM, Cuesta MA, Langendijk JA, van Riel JMGH, Pinedo HM, Peters GJ, Meijer S, Slotman BJ, Giaccone G: Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer 2002, 38:1212-1217.
28. Mohiuddin M, Kudrimou M, Regine WF, McGrath PC, Hanna N, John W: Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable G1 malignancy: A phase I study. Cancer J 2002, 8:255-262.
29. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, Brown D, Hejna G, Strawderman M, Normolle D, Lawrence TS: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001, 19:4202-4208.
30. Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, Mason K, Charnsangavej C, Pisters PWT, Lee JE, Lenzi R, Vauthey JN, Wong A, Phan T, Nguyen Q, Abbruzzese JL: Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatology 2001, 29:9-18.
31. Trodella L, Granone P, Valente S, Turriziani A, Macis G, Corbo GM, Margaritora S, Cesario A, D'Angelillo RM, Gualano G, Ramella S, Galetta D, Cellini N, Italian Cooperative Grp for the St and Cooperative German Austrian Swiss: Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol 2002, 20:804-810.
32. van Putten JWG, Groen HJM, Smid K, Peters GJ, Kampinga HH: End-joining deficiency and radiosensitization induced by gemcitabine. Cancer Res 2001, 61:1585-1591.
33. Wachters FM, van Putten JWG, Maring JG, Zdzienicka MZ, Groen HJM, Kampinga HH: Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Rad Oncol Biol Phys 2003, 57:553-562.
34. Robinson BW, Im MM, Ljungman M, Praz F, Shewach DS: Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Res 2003, 63:6935-6941.
35. van Bree C, Rodermond HM, de Vos J, Haveman J, Franken NA: Mismatch repair proficiency is not required for radioenhancement by gemcitabine. Int J Radiat Oncol Biol Phys 2005, 62:1504-9.
36. Eriksson S, Kierdaszuk B, Munch Petersen B, Oberg B, Johansson NG: Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 1991, 176:586-92.
37. Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM, Peters GJ: Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 1994, 54:4138-43.
38. Bergman AM, Pinedo HM, Jongsma APM, Brouwer M, Ruiz van Haperen VW, Veerman G, Leyva A, Eriksson S, Peters GJ: Decreased resistanceto gemcitabine (2 ′,2 ′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: Role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol 1999, 57:397-406.
39. Stegmann AP, Honders MW, Hagemeijer A, Hoebee B, Willemze R, Landegent JE: In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2′-deoxycytidine (DAC) in a rat modelfor acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Ann Hematol 1995, 71:41-7.
40. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R: Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Science 2004, 95:753-757.
41. Kroep JR, Loves WJP, van der Wilt CL, Alvarez E, Talianidis L, Boven E, Braakhuis BJM, van Groeningen CJ, Pinedo HM, Peters GJ: Pretreatment deoxycytidine kinase levels predict in vivogemcitabine sensitivity. Mol Cancer Ther 2002, 1:371-376.
42. Hapke DM, Stegmann AP, Mitchell BS: Retroviral transferof deoxycytidine kinase into tumor cell lines enhances nucleoside-toxicity. Cancer Res 1996, 56:2343-7.
43. Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW, Fine HA: Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med 1996, 2:567-73.
44. Stegmann AP, Honders WH, Willemze R, Ruiz van Haperen VW, Landegent JE: Transfection of wild-type deoxycytidine kinase (dck)cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity. Blood 1995, 85:1188-94.
45. van Moorsel CJA, Bergman AM, Veerman G, Voorn DA, Ruiz van Haperen VWT, Kroep JR, Pinedo HM, Peters GJ: Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines. Biochimica Et Biophysica Acta 2000, 1474:5-12.
46. van Bree C, Kreder NC, Loves WJP, Franken NAP, Peters GJ, Haveman J: Sensitivity to ionizing radiation andchemotherapeutic agents in gemcitabine-resistant human tumor cell lines. Int J Radiat Oncol Biol Phys 2002, 54:237-244.
47. Pauwels B, Korst AEC, de Pooter CMJ, Lambrechts HAJ, Pattyn GGO, Lardon F, Vermorken JB: The radiosensitising effect of gemcitabine andthe influence of the rescue agent amifostine in vitro. Eur J Cancer 2003, 39:838-846.
48. Shewach DS, Lawrence TS: Radiosensitization ofhuman tumor cells by gemcitabine in vitro. Semin Oncol 1995, 22:68-71.
49. Pauwels B, Korst AEC, de Pooter CMJ, Pattyn GGO, Lambrechts HAJ, Baay MFD, Lardon F, Vermorken JB: Comparison of the sulforhodamine Bassay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol 2003, 51:221-226.
50. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicityassay for anticancer-drug screening. J Natl Cancer Inst 1990, 82:1107-1112.
51. Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH: Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 1997, 208:151-158.
52. Spasokoukotskaja T, Arner ES, Brosjo O, Gunven P, Juliusson G, Liliemark J, Eriksson S: Expression of deoxycytidine kinase and-phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur J Cancer 1995, 31A:202-8.
53. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
54. Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA: Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 1996, 56:5198-5204.
55. Chou TC: The median-effect principle and the combination indexfor quantitation of synergism and antagonism. Synergism and Antagonism in Chemotherapy 1991:61-102.
56. Plunkett W, Huang P, Searcy CE, Gandhi V: Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996, 23:3-15.
57. van der Wilt CL, Kroep JR, Loves WJP, Rots MG, Van Groeningen CJ, Kaspers GJ, Peters GJ: Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver-metastases and normal liver. Eur J Cancer 2003, 39:691-697.
58. Gregoire V, Rosier JF, De Bast M, Bruniaux M, De Coster B, Octave Prignot M, Scalliet P: Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro. Radiother Oncol 2002, 63:329-338.
59. Robinson BW, Shewach DS: Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines. Clin Cancer Res 2001, 7:2581-2589.
60. Pauwels B, Korst AEC, Pattyn GGO, Lambrechts HAJ, Van Bockstaele DR, Vermeulen K, Lenjou M, DePooter CMJ, Vermorken JB, Lardon F: Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 2003, 57:1075-1083.
61. Mose S, Class R, Weber HW, Rahn A, Brady LW, Bottcher HD: Radiation enhancement by gemcitabine-mediated cell cycle modulations. Am J Clin Oncol 2003, 26:60-69.
62. Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, Kaspers GJ: The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 2005, 93:1388-94.